Cencora said revenue for the quarter ended December 31, 2023 rose $9.4 billion (15.0%) from the prior year quarter. Revenue at U.S. Healthcare Solutions rose $8.9 billion (15.9%), and it attributed $2.1 billion of the increase to sales of GLP-1-class products.

10-QQuarterly reportFiled Jan 31, 2024Period of report Dec 31, 2023Summary published (UTC) Oct 24, 2026

Key points

AI summary

Cencora said revenue for the quarter ended December 31, 2023 rose $9.4 billion (15.0%) from the prior year quarter. Revenue at U.S. Healthcare Solutions rose $8.9 billion (15.9%), and it attributed $2.1 billion of the increase to sales of GLP-1-class products.
The company said gross profit for the quarter rose $322.9 million (15.0%) from the prior year quarter. It cited increases in gross profit in both reportable segments and a LIFO credit in the current year quarter compared with LIFO expense in the prior year quarter as the main factors.
The company said total operating expenses for the quarter rose $133.1 million (8.8%) from the prior year quarter. It cited higher distribution, selling, and administrative expenses and amortization, and said a litigation and opioid-related credit was recorded in the current year quarter.
The company said net cash provided by operating activities for the quarter ended December 31, 2023 was $885.2 million. It said financing activities in the same quarter included purchases of its common stock of $385.5 million and cash dividends on its common stock of $105.7 million.

Key figures

Quarter ended December 31, 2023

Revenue: $72.3B
Operating income: $823M
Net income: $602M
EPS: $2.98
Gross profit: $2.5B
Operating cash flow: $885M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Quarterly Revenue Up $9.4 billion

Cencora said revenue for the quarter ended December 31, 2023 rose $9.4 billion (15.0%) from the prior year quarter. Revenue at U.S. Healthcare Solutions rose $8.9 billion (15.9%), and it attributed $2.1 billion of the increase to sales of GLP-1-class products.

Source · Based on the MD&A text of the filing

Gross Profit Up $322.9 million on LIFO Credit

The company said gross profit for the quarter rose $322.9 million (15.0%) from the prior year quarter. It cited increases in gross profit in both reportable segments and a LIFO credit in the current year quarter compared with LIFO expense in the prior year quarter as the main factors.

Source · Based on the MD&A text of the filing

Quarterly Operating Expenses and Litigation Credit

The company said total operating expenses for the quarter rose $133.1 million (8.8%) from the prior year quarter. It cited higher distribution, selling, and administrative expenses and amortization, and said a litigation and opioid-related credit was recorded in the current year quarter.

Source · Based on the MD&A text of the filing

Quarterly Operating Cash Flow and Shareholder Returns

The company said net cash provided by operating activities for the quarter ended December 31, 2023 was $885.2 million. It said financing activities in the same quarter included purchases of its common stock of $385.5 million and cash dividends on its common stock of $105.7 million.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.